This 2024 paper is a narrative review of cannabidiol, cannabis-derived products, regulation, pharmacology, and clinical use. It offers a useful overview of why purified CBD, commercial extracts, and broader cannabis products should not be treated as interchangeable. Its value is real, but it remains a narrative review, not a new trial, so its conclusions should be read as framing and synthesis rather than definitive proof.
CBD and Liver Enzymes: What the New JAMA Study Actually Shows
A new peer-reviewed study sent ripples through the CBD world—but what does it actually say about liver health? Spoiler: it’s not as simple as “CBD is dangerous.” When you zoom in on the details, the real story is about dose, data, and the difference between panic and perspective.